Antares Pharma, Inc. (ATRS)
| Market Cap | 753.68M |
| Revenue (ttm) | 158.60M |
| Net Income (ttm) | 62.35M |
| Shares Out | 167.82M |
| EPS (ttm) | 0.36 |
| PE Ratio | 12.54 |
| Forward PE | 33.44 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $4.45 |
| Previous Close | $4.47 |
| Change ($) | -0.02 |
| Change (%) | -0.45% |
| Day's Open | 4.49 |
| Day's Range | 4.43 - 4.50 |
| Day's Volume | 481,690 |
| 52-Week Range | 2.55 - 5.07 |
The FDA has accepted Antares Pharma Inc's (NASDAQ: ATRS) Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue. The active IND enables Antares to initiate a Phase 1 study f...
EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) h...
Ad hoc announcement pursuant to Art. 53 LR
EWING, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has submitted an Investigational New Drug ...
EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executiv...
EWING, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive...
Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 2.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice P...
Increased Revenue 27% Year-Over-Year to $42.1 Million
EWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of...
Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial ...
EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Exe...
In my opinion, choosing U.S.-listed securities that have the following characteristics represents a solid starting point when looking for potential value opportunities:
Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the...
EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year ...
EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
These interesting low-cost stocks have the opportunity to grow.
These companies offer more potential than the stock price might indicate.
EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...
Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript
Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020 financial ...
Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19.
Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.
Antares Expands Urology Portfolio and Leverages Commercial Organization Antares Expands Urology Portfolio and Leverages Commercial Organization
EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Exec...
Jack Howarth Retires as Vice President of Corporate Affairs Jack Howarth Retires as Vice President of Corporate Affairs
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q2 2020 Results - Earnings Call Transcript
Antares Pharma (NASDAQ: ATRS) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia.
EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with...
EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the Compan...
EWING, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the position...
Antares Continues To Quietly Grow Revenue
EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ray...
Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2020 Results - Earnings Call Transcript
First-quarter financial results failed to spark investors' animal spirits.
Antares Pharma: An Undervalued Stock To Buy During The COVID-19 Crisis
Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript
Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.
Antares Pharma: Reasonable Expectations For 2020
Antares Pharma: XYOSTED's Prescription Growth Is Running On All Cylinders
The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance
Investors are locking in gains in this fast-growing drugmaker.
EWING, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. ...
About ATRS
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active r... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Oct 2, 1996 |
| CEO Robert Apple | Employees 185 |
| Stock Exchange NASDAQ | Ticker Symbol ATRS |
Analyst Forecasts
According to 6 analysts, the average rating for Antares Pharma stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 46.07% from the latest price.